CN112877328B - 靶向atf5的小干扰rna及其用途 - Google Patents
靶向atf5的小干扰rna及其用途 Download PDFInfo
- Publication number
- CN112877328B CN112877328B CN202110105370.1A CN202110105370A CN112877328B CN 112877328 B CN112877328 B CN 112877328B CN 202110105370 A CN202110105370 A CN 202110105370A CN 112877328 B CN112877328 B CN 112877328B
- Authority
- CN
- China
- Prior art keywords
- atf5
- cells
- artificial sequence
- dna
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000905746 Homo sapiens Cyclic AMP-dependent transcription factor ATF-5 Proteins 0.000 title claims abstract description 50
- 102100023582 Cyclic AMP-dependent transcription factor ATF-5 Human genes 0.000 title claims abstract description 45
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 36
- 239000004055 small Interfering RNA Substances 0.000 title claims abstract description 35
- 230000008685 targeting Effects 0.000 title claims abstract description 15
- 230000035772 mutation Effects 0.000 claims abstract description 40
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 18
- 230000002441 reversible effect Effects 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000002188 osteogenic effect Effects 0.000 claims description 8
- 230000004898 mitochondrial function Effects 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 abstract description 25
- 210000004027 cell Anatomy 0.000 description 74
- 108020004414 DNA Proteins 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 108010058432 Chaperonin 60 Proteins 0.000 description 10
- 102000006303 Chaperonin 60 Human genes 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 9
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 9
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 9
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 9
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 description 9
- 238000003197 gene knockdown Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 102000005869 Activating Transcription Factors Human genes 0.000 description 6
- 101000814380 Homo sapiens Protein Wnt-7b Proteins 0.000 description 6
- 102100039470 Protein Wnt-7b Human genes 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000004906 unfolded protein response Effects 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108020005087 unfolded proteins Proteins 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 229910001868 water Inorganic materials 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 102000038624 GSKs Human genes 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 101710134930 Import motor subunit, mitochondrial Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101150008849 LONP1 gene Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 1
- 206010059396 Mitochondrial DNA depletion Diseases 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002779 membrane potential assay Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 230000006807 siRNA silencing Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Forward | Reverse | |
ATF5 | ctggctccctatgaggtccttg | gagctgtgaaatcaactcgctcag |
mtHSP70 | caagcgacaggctgtcaccaac | caacccaggcatcaccattgg |
HSP60 | gatgctgtggccgttacaatg | gtcaattgactttgcaacagtcacac |
Lonp1 | cattgccttgaaccctctc | atgtcgctcaggtagatgg |
Runx2 | ccaacccacgaatgcactatc | tagtgagtggtggcggacatac |
BMP2 | gagaaggaggaggcaaagaaa | agcagcaacgctagaagacag |
OCN | ccccctctagcctaggacc | accaggtaatgccagtttgc |
GSK-3g | ccttaacctggtgctggact | agctctggtgccagta |
Wnt-7b | caacgagtgccagtaccagttcc | atctcccgagcgtccacgaag |
β-actin | catgtacgttgctatccaggc | ctccttaatgtcacgcacgat |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110105370.1A CN112877328B (zh) | 2021-01-26 | 2021-01-26 | 靶向atf5的小干扰rna及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110105370.1A CN112877328B (zh) | 2021-01-26 | 2021-01-26 | 靶向atf5的小干扰rna及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112877328A CN112877328A (zh) | 2021-06-01 |
CN112877328B true CN112877328B (zh) | 2022-07-19 |
Family
ID=76052214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110105370.1A Active CN112877328B (zh) | 2021-01-26 | 2021-01-26 | 靶向atf5的小干扰rna及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112877328B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109554335A (zh) * | 2018-12-04 | 2019-04-02 | 上海市第六人民医院 | 线粒体mt3243AG突变人群的尿液中分离培养正常的干细胞的制备方法和应用 |
CN111269883A (zh) * | 2020-02-27 | 2020-06-12 | 上海市东方医院(同济大学附属东方医院) | 一种线粒体mt.3243A>G突变人群中高突变尿液干细胞的制备方法 |
-
2021
- 2021-01-26 CN CN202110105370.1A patent/CN112877328B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109554335A (zh) * | 2018-12-04 | 2019-04-02 | 上海市第六人民医院 | 线粒体mt3243AG突变人群的尿液中分离培养正常的干细胞的制备方法和应用 |
CN111269883A (zh) * | 2020-02-27 | 2020-06-12 | 上海市东方医院(同济大学附属东方医院) | 一种线粒体mt.3243A>G突变人群中高突变尿液干细胞的制备方法 |
Non-Patent Citations (2)
Title |
---|
Accession No. NM_012068.6,Homo sapiens activating transcription factor 5 (ATF5), transcript variant 1, mRNA;Gaither K等;《GenBank》;20201029;第4页ORIGIN部分 * |
Mitochondrial Nuclear Retrograde Regulator 1;Siddhesh Aras;《Proc Natl Acad Sci U S A》;20201215;第115卷(第50期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN112877328A (zh) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9388466B2 (en) | Precursor miRNA loop-modulated target regulation | |
US9662314B2 (en) | Compounds and methods for the treatment of muscular disease, and related screening methods | |
EP2077326A1 (en) | Novel nucleic acid | |
CN106488777A (zh) | 用于心脏肥大治疗和诊断的LncRNA | |
CN105903036B (zh) | miR-130a反义核酸及其衍生物在Hippo-YAP信号通路抑制剂中的应用 | |
EP2314678B1 (en) | Micro-rna associated with rheumatoid arthritis | |
WO2014111876A2 (en) | Modulation of mitophagy and use thereof | |
Yin et al. | lncRNA MALAT1 mediates osteogenic differentiation of bone mesenchymal stem cells by sponging miR-129-5p | |
WO2008053909A1 (fr) | Agent destiné à réguler la croissance et/ou la différenciation d'une cellule souche mésenchymateuse | |
CN112877328B (zh) | 靶向atf5的小干扰rna及其用途 | |
Ye et al. | MiR-126 enhances VEGF expression in induced pluripotent stem cell-derived retinal neural stem cells by targeting spred-1 | |
CN112680511B (zh) | Atf5在筛选用于治疗线粒体基因3243位点突变相关疾病的药物中的用途 | |
CN115927583B (zh) | 一种认知障碍相关疾病生物标志物miR-32533及其应用 | |
CN114959057B (zh) | 与猪骨骼肌卫星细胞增殖相关的circRNA及其应用 | |
KR101268478B1 (ko) | Dkk3 발현 또는 활성 억제제를 함유하는 암 예방 및 치료용 조성물 | |
US9567634B2 (en) | Method for detecting or measuring the impact of a viral vector composition on eukaryotic cells and biomarkers used thereof | |
CN109722435B (zh) | 胰岛长链非编码RNA 1810019D21Rik及其应用 | |
CN113227375A (zh) | 合成的微小rna模拟物 | |
CN112522396A (zh) | 一种piRNA NU13作为检测靶点的儿童胚胎性恶性肿瘤诊断试剂 | |
Kanadia et al. | Alternative splicing produces high levels of noncoding isoforms of bHLH transcription factors during development | |
CN111118139B (zh) | 一种骨质疏松的分子靶标及其应用 | |
CN113564253B (zh) | circ_0000173作为卵巢癌预后、治疗标志物的应用 | |
Lyu et al. | CRISPR/Cas9-based knockout of miR-487b-3p accelerates the cell proliferation of primary goat myoblast by relieving its inhibition of IRS1 | |
CN107916252B (zh) | 一株用于验证脊肌萎缩症的永生淋巴细胞株 | |
CN107604065B (zh) | 一种肝癌miRNA标记物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231112 Address after: Room 109D, No. 1121 Zhongshan North Second Road, Yangpu District, Shanghai, 200433 Patentee after: Shanghai AI porcon Biological Technology Co.,Ltd. Address before: No. 1279, Sanmen Road, Hongkou District, Shanghai 200434 Patentee before: SHANGHAI FOURTH PEOPLE'S Hospital |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240514 Address after: 200335 First Floor, No. 7, Lane 128, Linhong Road, Changning District, Shanghai Patentee after: Noah Ke (Shanghai) Biopharmaceutical Technology Co.,Ltd. Country or region after: China Address before: Room 109D, No. 1121 Zhongshan North Second Road, Yangpu District, Shanghai, 200433 Patentee before: Shanghai AI porcon Biological Technology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |